Please select the option that best describes you:
Topics:
Gynecologic Oncology • Medical Oncology
Would you consider adding immunotherapy to adjuvant chemotherapy in a patient with incompletely staged, high-grade, MSI-H, POLE-mutated endometrioid carcinoma of the ovary with ultra-high tumor mutation burden on NGS?
Would single-agent ICI suffice? Is there any benefit to ICI in the absence of residual disease post-surgery?
Patient is s/p TAH/BSO. Postoperative imaging shows no gross evidence of disease.